Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="JANSSENS, A" or (type any "bookEditor journalEditor issueEditor" and editor="JANSSENS, A")

Add to list
- Conference Paper
- C3
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

J Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, et al.

(2016) ONCOLOGY RESEARCH AND TREATMENT. 39(suppl. 3). p.6-6
Add to list
- Conference Paper
- C3
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

P Hillmen, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, NL Bartlett, J Li, D Simpson, et al.

(2016) BRITISH JOURNAL OF HAEMATOLOGY. 173(suppl. 1). p.7-7
Add to list
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

A Chanan-Khan, P Cramer, F Demirkan, G Fraser, RS Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, NL Bartlett, et al.

(2016) LANCET ONCOLOGY. 17(2). p.200-211
Add to list
Integrating early palliative care (EPC) in the management of lung cancer: the role of the thoracic oncologist

A Janssens, L Teugels, S Kohl, T Michielsen and Jan Van Meerbeeck (UGent)

(2015) LUNG CANCER. 90(2). p.135-138
Add to list
- Conference Paper
- C3
Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial

BM Chelliah Jebaraj, E Tausch, R Schlenk, S Kless, C Galler, P Hillmen, Fritz Offner (UGent) , A Janssens, T Zenz, K Govindbabu, et al.

(2015) HAEMATOLOGICA. 100(suppl. 1). p.226-226
Add to list
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, et al.

(2015) NEW ENGLAND JOURNAL OF MEDICINE. 373(25). p.2425-2437
Add to list
- Conference Paper
- C3
SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)

E Tausch, C Galler, RF Schlenk, P Hillmen, Fritz Offner (UGent) , A Janssens, K Govindbabu, S Grosicki, J Mayer, P Panagiotidis, et al.

(2014) HAEMATOLOGICA. 99(suppl. 1). p.522-523
Add to list
The value of endoscopic ultrasound after bronchoscopy to diagnose thoracic sarcoidosis

Kurt Tournoy (UGent) , A Bolly, JG Aerts, P Pierard, R De Pauw, D Leduc, A Leloup, T Pieters, H Slabbynck, A Janssens, et al.

(2010) EUROPEAN RESPIRATORY JOURNAL. 35(6). p.1329-1335
Add to list
- Journal Article
- A1
Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia

FEMKE VAN BOCKSTAELE (UGent) , Valerie Pede (UGent) , A JANSSENS, F CALLEWAERT, Fritz Offner (UGent) , Bruno Verhasselt (UGent) and Jan Philippé (UGent)

(2007) CLINICAL CHEMISTRY. 53(2). p.204-212
Add to list
- Journal Article
- A1
EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient

A JANSSENS, M BERTH, P DE PAEPE, Bruno Verhasselt (UGent) , Nadine Van Roy (UGent) , Lucien Noens (UGent) , Jan Philippé (UGent) and Fritz Offner (UGent)

(2006) AMERICAN JOURNAL OF HEMATOLOGY. 81(9). p.706-712

Academic Bibliography

International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Integrating early palliative care (EPC) in the management of lung cancer: the role of the thoracic oncologist

Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)

The value of endoscopic ultrasound after bronchoscopy to diagnose thoracic sarcoidosis

Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia

EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient

Contents

Support

Contact